Suzhou Ribo Life Science FY2025 administrative expenses jump 28% to RMB118 million; revenue rises 4.1% to RMB149 million

Reuters03-25

Suzhou Ribo Life Science FY2025 administrative expenses jump 28% to RMB118 million; revenue rises 4.1% to RMB149 million

Suzhou Ribo Life Science posted FY2025 loss before tax that widened 10.7% to RMB285 million.
FY2025 administrative expenses jumped 28% to RMB118 million on higher listing expenses and increased professional and consulting service fees.
FY2025 loss per share widened to RMB2.11 from RMB2.10.
FY2025 revenue rose 4.1% to RMB149 million on higher collaboration revenue from the Boehringer Ingelheim agreement and higher sales of nucleoside monomers-related products.
FY2025 gross profit climbed 3.3% to RMB135 million, while gross profit margin fell 0.8 percentage points to 90.9%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260325-12067623), on March 25, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622725680?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 22:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622725680","market":"nz","top_or_hot":-1,"title":"Suzhou Ribo Life Science FY2025 administrative expenses jump 28% to RMB118 million; revenue rises 4.1% to RMB149 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Suzhou Ribo Life Science FY2025 administrative expenses jump 28% to RMB118 million; revenue rises 4.1% to RMB149 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Suzhou Ribo Life Science posted FY2025 loss before tax that widened 10.7% to RMB285 million.\n        </li>\n<li>\n          FY2025 administrative expenses jumped 28% to RMB118 million on higher listing expenses and increased professional and consulting service fees.\n        </li>\n<li>\n          FY2025 loss per share widened to RMB2.11 from RMB2.10.\n        </li>\n<li>\n          FY2025 revenue rose 4.1% to RMB149 million on higher collaboration revenue from the Boehringer Ingelheim agreement and higher sales of nucleoside monomers-related products.\n        </li>\n<li>\n          FY2025 gross profit climbed 3.3% to RMB135 million, while gross profit margin fell 0.8 percentage points to 90.9%.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260325-12067623), on March 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Suzhou Ribo Life Science FY2025 administrative expenses jump 28% to RMB118 million; revenue rises 4.1% to RMB149 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSuzhou Ribo Life Science FY2025 administrative expenses jump 28% to RMB118 million; revenue rises 4.1% to RMB149 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-25 22:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Suzhou Ribo Life Science FY2025 administrative expenses jump 28% to RMB118 million; revenue rises 4.1% to RMB149 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Suzhou Ribo Life Science posted FY2025 loss before tax that widened 10.7% to RMB285 million.\n        </li>\n<li>\n          FY2025 administrative expenses jumped 28% to RMB118 million on higher listing expenses and increased professional and consulting service fees.\n        </li>\n<li>\n          FY2025 loss per share widened to RMB2.11 from RMB2.10.\n        </li>\n<li>\n          FY2025 revenue rose 4.1% to RMB149 million on higher collaboration revenue from the Boehringer Ingelheim agreement and higher sales of nucleoside monomers-related products.\n        </li>\n<li>\n          FY2025 gross profit climbed 3.3% to RMB135 million, while gross profit margin fell 0.8 percentage points to 90.9%.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260325-12067623), on March 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06938","symbol_name":"瑞博生物-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDLFDTsT:1","article_id":"2622725680","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622725680","pubTimestamp":1774448990,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Suzhou Ribo Life Science posted FY2025 loss before tax that widened 10.7% to RMB285 million.FY2025 administrative expenses jumped 28% to RMB118 million on higher listing expenses and increased professional and consulting service fees.FY2025 loss per share widened to RMB2.11 from RMB2.10.FY2025 revenue rose 4.1% to RMB149 million on higher collaboration revenue from the Boehringer Ingelheim agreement and higher sales of nucleoside monomers-related products.FY2025 gross profit climbed 3.3% to RMB135 million, while gross profit margin fell 0.8 percentage points to 90.9%.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Infor","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06938":"瑞博生物-B","BK1161":"生物科技"},"translate_title":"苏州日博生命科学2025财年管理费用增长28%至人民币1.18亿元；收入增长4.1%至人民币1.49亿元","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06938":0.9},"content_text":"Suzhou Ribo Life Science FY2025 administrative expenses jump 28% to RMB118 million; revenue rises 4.1% to RMB149 million\n    \n\n\n          Suzhou Ribo Life Science posted FY2025 loss before tax that widened 10.7% to RMB285 million.\n        \n\n          FY2025 administrative expenses jumped 28% to RMB118 million on higher listing expenses and increased professional and consulting service fees.\n        \n\n          FY2025 loss per share widened to RMB2.11 from RMB2.10.\n        \n\n          FY2025 revenue rose 4.1% to RMB149 million on higher collaboration revenue from the Boehringer Ingelheim agreement and higher sales of nucleoside monomers-related products.\n        \n\n          FY2025 gross profit climbed 3.3% to RMB135 million, while gross profit margin fell 0.8 percentage points to 90.9%.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260325-12067623), on March 25, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622725680","isCrawlerRequest":true}